Literature DB >> 24142858

Legionella pneumophila pneumonia during telaprevir-based triple therapy for HCV chronic hepatitis.

T Tieghi1, R Marocco, V Belvisi, C Del Borgo, S Savinelli, M Lichtner, C M Mastroianni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24142858     DOI： 10.1007/s15010-013-0543-7

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  5 in total

1.  Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.

Authors:  G Mancini; L Erario; R Gianfreda; A Oliva; A P Massetti; C M Mastroianni; V Vullo
Journal:  Clin Microbiol Infect       Date:  2007-08-17       Impact factor: 8.067

2.  Tuberculous sepsis during antiviral HCV triple therapy.

Authors:  Stephanie Hametner; Fabio Monticelli; Jan Marco Kern; Rainer Schöfl; Alexander Ziachehabi; Andreas Maieron
Journal:  J Hepatol       Date:  2013-05-10       Impact factor: 25.083

3.  Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

Authors:  Christophe Hézode; Hélène Fontaine; Céline Dorival; Dominique Larrey; Fabien Zoulim; Valérie Canva; Victor de Ledinghen; Thierry Poynard; Didier Samuel; Marc Bourlière; Jean-Pierre Zarski; Jean-Jacques Raabe; Laurent Alric; Patrick Marcellin; Ghassan Riachi; Pierre-Henri Bernard; Véronique Loustaud-Ratti; Sophie Métivier; Albert Tran; Lawrence Serfaty; Armand Abergel; Xavier Causse; Vincent Di Martino; Dominique Guyader; Damien Lucidarme; Véronique Grando-Lemaire; Patrick Hillon; Cyrille Feray; Thong Dao; Patrice Cacoub; Isabelle Rosa; Pierre Attali; Ventzislava Petrov-Sanchez; Yoann Barthe; Jean-Michel Pawlotsky; Stanislas Pol; Fabrice Carrat; Jean-Pierre Bronowicki
Journal:  J Hepatol       Date:  2013-05-10       Impact factor: 25.083

Review 4.  The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

Authors:  Kristen M Marks; Ira M Jacobson
Journal:  Antivir Ther       Date:  2012-10-05

5.  Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.

Authors:  Benjamin Maasoumy; Kerstin Port; Antoaneta Angelova Markova; Beatriz Calle Serrano; Magdalena Rogalska-Taranta; Lisa Sollik; Carola Mix; Janina Kirschner; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.